WuXi PharmaTech (WX) Boosts FY14 Revs Outlook

WuXi PharmaTech (NYSE: WX) announced that it has updated its 2014 financial guidance. The company expects to achieve total revenues for full-year 2014 of approximately $674 million, compared to previous guidance of $670-672 million. The company expects to achieve diluted EPS of approximately $1.87 (non-GAAP) and approximately $1.56 (GAAP), compared to previous guidance of 1.83-1.86 (non-GAAP) and $1.55-1.58 (GAAP). These preliminary 2014 results are unaudited and remain subject to the finalization of the company's year-end closing, reporting, and audit processes. The company plans to report its fourth-quarter and full-year 2014 financial results and to provide 2015 financial guidance in March 2015.

The company also announced that it will present at the 33th annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 1:30 p.m. Pacific Standard Time. The company's slides from the conference will be available on the company's Investor Relations page at www.wuxiapptec.com.

You May Also Be Interested In

• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Luna Innovations (LUNA) Announces Restatement of Financial Statements
• Norfolk Southern (NSC) corrects Ancora's false and misleading statements